| |
 |
|
Key to the future success of any pharmaceutical company
is a strong pipeline of new products. In addition to the
significant contribution from the STADA pipeline, Genus
has its own business development team focusing on local
product opportunities.
|
| |
Brands
Having successfully acquired and integrated several brands
in 2006, Genus is actively looking to expand its branded portfolio
of products. In particular, there is an interest in existing,
marketed products, or molecules which are clinically proven
(beyond Phase III), preferably with registrations approved
or ongoing. |
| |
Generics
Genus' generic in-licensing focuses on several areas:
- Where UK requirements are different from Group (i.e.
an alternate presentation)
- Products with licensing requirements peculiar to the
UK market
- Products not sourced by Group (including niche or hospital
products)
For more information, please contact the
|
|
|
